Average weekly prevalence (percentage of athletes affected) of all health problems and substantial problems reported, as well as the prevalence of the subcategories illness, injury, overuse injury and acute injury in the whole group and each of the four subgroups of athletes
Team | Endurance | Tactical/technical | Paralympic | Total cohort | |
---|---|---|---|---|---|
n=30 | n=53 | n=36 | n=26 | n=142 | |
Health problems reported | |||||
All | 45 (42–48)**,***,**** | 30 (27–32)*,*** | 25 (21–28)*,** | 29 (26–33)* | 36 (34–38) |
Illness | 6 (5–8)**,***,**** | 16 (13–18)*,*** | 10 (9–12)*,**,**** | 16 (14–19)*,*** | 13 (12–14) |
Injury | 42 (39–45)**,***,**** | 17 (16–19)* | 18 (14–22)* | 19 (17–21)* | 25 (24–27) |
Overuse injury | 31 (29–33)**,***,**** | 15 (13–17)* | 16 (13–18)* | 13 (12–14)*,** | 20 (18–21) |
Acute injury | 10 (8–12)**,***,**** | 2 (1–2)* | 3 (2–4)* | 2 (1–3)* | 4 (3–5) |
Substantial problems | |||||
All | 16 (14–17)*** | 14 (13–16)*** | 11 (9–13)*,**,**** | 16 (14–19)*** | 15 (14–16) |
Illness | 2 (1–3)**,***,**** | 8 (6–10)* | 6 (5–8)* | 8 (6–10)* | 6 (6–7) |
Injury | 14 (13–16)**,***,**** | 7 (6–7)* | 5 (4–7)*,**,**** | 11 (9–12)*,**,*** | 9 (9–10) |
Overuse injury | 9 (8–11)**,*** | 6 (5–6)* | 4 (3–5)*,**,**** | 10 (8–11)**,*** | 7 (6–8) |
Acute injury | 5 (4–6)**,***,**** | 1 (0–1)* | 2 (1–2)* | 1 (0–2)* | 2 (2–3) |
p<0.05 vs *team group, **endurance group, ***tactical/technical group, ****paralympic group.
All data are mean values with 95% CI in parenthesis. Substantial problem: causing moderate/severe reductions in training volume or sports performance, or complete inability to participate in training or competition.